Clinical Trial Update: A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure [Phase 3]

View source ↗

Summary

A Phase 3 dose-ranging trial evaluating the safety and efficacy of aliskiren for hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Aliskiren (Aliskiren)

Snippet

Sponsor: Novartis | Conditions: Hypertension | Phase 3 | Status: COMPLETED